N Neungton

Mahidol University, Krung Thep, Bangkok, Thailand

Are you N Neungton?

Claim your profile

Publications (8)7.49 Total impact

  • C Permpikul · R Ratanarat · N Neungton
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with tissue perfusion deficit usually have lactic acidosis or hyperlactacidemia and blood lactate level has been used to diagnose this condition and to monitor the disease progression. We conducted a study to examine the diagnostic accuracy of capillary and arterial lactate (C LAC and strip A LAC) obtained by using a portable lactate analyzer (Accusport) compared with the standard method (A LAC) in this condition. Forty eight patients were included in the study. Strong correlation between C LAC and A LAC as well as strip A LAC and A LAC were demonstrated (r = 0.89 and 0.98 respectively, p <0.05). When determining agreement between C LAC and strip A LAC with the standard method, all but 2 of C LAC - A LAC differences and 2 of strip A LAC - A LAC differences were within the agreement limits (mean +/- 2SD). We conclude that capillary and arterial lactate determined by the tested device, when used and interpreted cautiously, can substitute arterial lactate in the diagnosis of hyperlactacidemia and monitoring the effectiveness of therapy.
    No preview · Article · Dec 2000 · Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [Show abstract] [Hide abstract]
    ABSTRACT: Kearns-Sayre syndrome is one of the neurological diseases caused by a defect in the energy-producing system of mitochondria. Keams-Sayre is known to be associated with a deletion in the mitochondrial genome and is usually detected in muscle biopsies of the patients. In this study, we report the molecular lesion of mitochondrial DNA (mtDNA) in four Thai patients admitted to hospital with encephalomyopathies. The 3.5-kb deletion of mtDNA was detected by Southern analysis, mapped by amplification with five primer pairs covering almost the total mitochondrial genome, and confirmed by PCR primer shift analysis. The deleted position was localized to nt 10208/13765 or nt 10204/13761 spanning the coding area of subunits 3 (ND3), 4L (ND4L), 4 (ND4), and 5 (ND5) of respiratory chain enzyme complex I and the tRNA genes for histidine, serine, leucine, and arginine. The sequence flanking the deletion was a 4-bp repeat of TCCC. All four patients have exactly the same 3558-bp mtDNA deletion; this is the only deleted position in their mtDNA but is different from those reported in the literature. The deletion seems to be found only in Thai patients, although they present with different clinical manifestations and none of them is not related.
    No preview · Article · Aug 1999 · Human Genetics
  • [Show abstract] [Hide abstract]
    ABSTRACT: Leber's hereditary optic neuropathy (LHON) is a maternally transmitted disease, characterized by bilateral optic atrophy predominantly in healthy young males. This disorder has shown to be associated with DNA mutation in mitochondrial genome of the patients. We report here a young man who came to the hospital with subacute visual loss in one eye, followed by the other eye within two months. His echocardiogram was normal. A G-->A base substitution at nucleotide position 11,778 which changes a conserved arginine to histidine at amino acid position 340 of ND4, a protein subunit of respiratory chain enzyme complex I in oxidative phosphorylation system, was detected in his leucocyte mitochondrial genome.
    No preview · Article · Jan 1999 · Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Two newly established murine monoclonal antibodies (MAbs), OVS1 and OVS2, to human ovarian mucinous cystadenocarcinoma were further characterized for diagnostic efficacy. The specific SA-1 antigen, purified from the tumor extract was identified as a glycoprotein of 29 kDa. A double determinant biotinstreptavidin alkaline phosphatase immunoassay system, containing OVS1 and OVS2 MAbs was used to determine the SA-1 levels in serum. The OVS1 MAb was used as a first antibody because of its high specificity of 96% while OVS2 MAb, with a lower specificity of 8% but greater sensitivity of 78%, was chosen as a second antibody. Matched sera of 64 healthy controls and 90 patients with definite diagnoses of 25 benign diseases, 14 nonovarian cancer and 51 ovarian cancer, were simultaneously measured together with CA 125 values. At cut-off levels of 220 and 360 units/ml, the SA-1 test showed 63% and 43% positive rates respectively in all types of ovarian cancer, compared to 65% and 57% positive rates for CA 125 at cut-off levels of 35 and 60 units/ml, respectively. Sensitivity for SA-1 at 220 units/ml cut-off level in mucinous ovarian cancer was 75% and increased significantly to 85% when the test was combined with CA 125 at 35 units/ml cut-off level. Furthermore, The combination of both tests significantly increased the positive rates to 86% in all types of early stage ovarian cancer.(ABSTRACT TRUNCATED AT 250 WORDS)
    Preview · Article · Jul 1995 · Asian Pacific journal of allergy and immunology / launched by the Allergy and Immunology Society of Thailand
  • [Show abstract] [Hide abstract]
    ABSTRACT: We analysed the mitochondrial genome of one patient with chronic and progressive bilateral ophthalmoplegia. This patient also had abnormal EKG showing cardiac conduction defects and pigmentary retinopathy, suggestive of the Kearns-Sayre syndrome. On muscle biopsy, with Gomori trichrome stain, the fibers showed an increase in red-staining material in the intermyofibrillary network and the subsarcolemmal region. On electron microscopy, aggregations of abnormal mitochondria were demonstrated, confirming the diagnosis of mitochondrial myopathy. Analysis of mitochondrial DNA (mtDNA) from the patient and her mother showed no deleted mtDNA.
    No preview · Article · Feb 1995 · The Southeast Asian journal of tropical medicine and public health
  • [Show abstract] [Hide abstract]
    ABSTRACT: From 1989 to 1991, 68 cirrhotic patients, 47 with uninfected ascites and 21 with SBP were studied for the significance of ascitic fluid pH, lactate, PMN count and other chemistry for immediate diagnosis of SBP. It was revealed that ascitic fluid PMN count if over 500 per mm3, the increased lactate, or decreased glucose level, strongly supported the diagnosis of SBP. In cases of suspecting SBP but with low PMN count the ascitic values of lactate, glucose and pH will guide the diagnosis. If the ascitic lactate plus glucose, or lactate plus pH are above the cut off levels (lactate > 25 mg/dl; glucose < 60 mg/dl and pH < 7.35) the diagnosis is strongly suggestive. The ascitic fluid pH and A-AF pH gradient were not of diagnostic value due to instability of pH after tapping. For other chemistry in the ascitic fluid, there was a slight increase in ADA level in SBP, but for glucose, protein and glutamine levels, there was no difference among the groups with and without SBP.
    No preview · Article · Jun 1994 · Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [Show abstract] [Hide abstract]
    ABSTRACT: OVS1 and OVS2 monoclonal antibodies (MAbs) were established by fusing murine myeloma cell line NS1/1-Ag4-1 with mouse spleen cells immunized with fresh human ovarian mucinous-cystadenocarcinoma tissue. The selection of the MAbs was assayed by an immuno-histological (streptavidin-biotin) staining of the specific antigen antibody reaction localized on frozen sections of the same tumor. Other paraffin sections and established cell lines were also screened by immuno-histological staining in order to characterize the specificity and sensitivity of these two MAbs. OVS1 MAb showed 96% specificity and 67% sensitivity to mucinous cystadenocarcinoma with no cross reactions to normal tissue, benign tissue, other cancers, or any established cell lines. OVS2 MAb revealed only 8% specificity but 78% sensitivity to mucinous cystadenocarcinoma, however, a cross reaction to some normal and benign tissues or other cancers was shown. The data suggested that OVS1 and OVS2 MAbs could be used in combination to detect ovarian mucinous cystadenocarcinoma.
    No preview · Article · Jan 1993 · Asian Pacific journal of allergy and immunology / launched by the Allergy and Immunology Society of Thailand
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer is ranked among the top three causes of death in Thailand. The research has been focused to improve the diagnosis and treatment of cancers. Monoclonal antibodies could become one of the major tools to achieve the satisfied outcome. OVS1 monoclonal antibody (MAb) produced against ovarian cancer was used to identify the mucinous cystadenocarcinoma antigen as a tumor marker secreted in serum. Since breast and ovarian cancers shared various associate markers, the potential of OVS1 MAb in ovarian and breast cancer treatments was determined. MTT assay was employed to measure the cytotoxicity against breast (BT549), ovarian (SKOV3) and endothelial (ECV304) cell lines. Paclitaxel, an anti-tumor drug, and α-mangostin, a natural purified constituent from Garcinia mangostana pericarp, were tested as MAb-drug conjugation. The binding efficiency of OVS1-α-mangostin to the cancer cells was monitored by fluorescein-5-isothiocyanate (FITC). Furthermore, the apoptosis of cancer cell lines was examined using fluorimetric assay and confirmed by DNA fragmentation in gel electrophoresis. The ED 50 of α-mangostin were 3.5 and 3.4 μg/ml, while the ED 50 of MAb-α-mangostin conjugation (MAb-drug conjugation) were 29.6 and 42.8 μg/ml against SKOV3 and ECV304, respectively. Although the ED 50 of MAb-drug (α-mangostin) conjugation was higher than that of α-mangostin alone, the binding efficiency and specificity of MAb-α-mangostin to SKOV3 cancer cells were satisfactory as monitored using FITC. Furthermore, the ED 50 of MAb-α-mangostin conjugation against SKOV3 cancer cell showed significant lower value than that against ECV304 endothelial cell line. This study supported the potential application of MAb-drug or -medicinal plant conjugation as anti-cancer drug for targeted cancer therapy. ©All right reserved.
    Preview · Article ·